Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of baxdrostat for uncontrolled or resistant hypertension
NL-OMON58993Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of baxdrostat in hypertension (HTN) and resistant hypertension (RH) (3 arms), sponsored by AstraZeneca. Primary endpoints: Change from baseline in seated systolic blood pressure for 2 mg baxdrostat, Change from baseline in seated systolic blood pressure for 1 mg baxdrostat and 1 more. Started Mar 2024; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on NL-OMON58993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58993.